Strides Shasun gets USFDA nod for pain reliever drug
New Delhi: Strides Shasun has got approval from the US health regulator for pain reliever drug ibuprofen.
The product will be marketed by Strides Pharma Inc in the US market under its OTC brand Nuprin, Strides Shasun said in a BSE filing.
Quoting IRi data, the drug firm said that the US market for ibuprofen tablets USP 200 mg is approximately $520 million.
Strides Shasun stock was trading higher by 4.71 per cent at Rs. 947.95 on the BSE.
The product will be marketed by Strides Pharma Inc in the US market under its OTC brand Nuprin, Strides Shasun said in a BSE filing.
Quoting IRi data, the drug firm said that the US market for ibuprofen tablets USP 200 mg is approximately $520 million.
Strides Shasun stock was trading higher by 4.71 per cent at Rs. 947.95 on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd